<DOC>
	<DOCNO>NCT00002658</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Biological therapy use different way stimulate immune system stop cancer cell grow . Combining chemotherapy bone marrow transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Randomized phase III trial compare effectiveness different treatment regimen treat patient acute myeloid leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy , Biological Therapy , Bone Marrow Transplantation Treating Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Compare remission rate , duration remission , survival , toxicity , supportive care requirement associate induction chemotherapy cytarabine , daunorubicin , etoposide v mitoxantrone , cytarabine , etoposide patient acute myeloid leukemia . - Assess filgrastim ( G-CSF ) support recovery phase first induction course respect remission rate , reason failure , hematologic regeneration , febrile incident , supportive care requirement , overall survival patient . - Compare 4 v 5 course total treatment , either chemotherapy bone marrow transplantation ( BMT ) final course , respect remission duration , relapse rate , disease free mortality , overall survival patient . - Compare allogeneic autologous BMT v conventional chemotherapy respect remission duration , relapse rate , disease free mortality , overall survival patient . - Evaluate prognostic significance blood bone marrow morphology , cytogenetics , molecular genetics , immunophenotype assess diagnosis , second randomization , relapse . OUTLINE : This randomize study . Patients stratify center , age ( 15-29 v 30-39 vs 40-49 v 50-59 ) , performance status , disease status ( de novo v secondary ) . Patients eligible second randomization also stratify first randomization treatment ( arm I vs II ) prognostic risk group ( good v standard ) . Original first randomization ( close 11/1998 ) : Patients randomize 1 2 induction treatment arm . - Arm I : During course 1 , patient receive cytarabine IV every 12 hour day 1-10 , daunorubicin IV day 1 , 3 , 5 , etoposide IV 1 hour day 1-5 . Patients randomize receive either filgrastim ( G- CSF ) placebo subcutaneously ( SQ ) begin day 18 continue 2 day blood count recover ( G-CSF randomization close 8/15/2000 ) . During course 2 , patient receive daunorubicin etoposide course 1 cytarabine IV every 12 hour day 1-8 , G-CSF placebo unless peripheral blood stem cell ( PBSC ) harvest . - Arm II : During course 1 , patient receive mitoxantrone IV day 1 , 3 , 5 cytarabine , etoposide , G-CSF placebo course 1 arm I . During course 2 , patient receive mitoxantrone etoposide course 1 arm II , cytarabine course 2 arm I , G-CSF placebo unless PBSC harvest . Patients poor prognostic risk course 1 fail achieve complete remission ( CR ) course 2 take study enter MRC refractory/relapse study . Patients achieve CR course 1 proceed harvest phase completion course 2 . Patients achieve CR course 2 proceed postinduction chemotherapy phase . New first randomization ( opened 12/1998 ) : Patients randomize 1 2 induction treatment arm . - Arm I : During course 1 , patient receive daunorubicin IV day 1 , 3 , 5 low dose cytarabine IV every 12 hour thioguanine IV every 12 hour day 1-10 . During course 2 , patient receive treatment course 1 , cytarabine thioguanine day 1-8 . - Arm II : During course 1 2 , patient receive treatment arm I , high dose cytarabine . Both arm may randomize receive tretinoin tretinoin 60 day . Acute prophylactic subgroup randomize receive tretinoin . - Postinduction chemotherapy : Patients receive amsacrine IV 1 hour , cytarabine IV continuously , etoposide IV 1 hour day 1-5 . - Harvest : Patients HLA match sibling donor undergo allogeneic bone marrow transplantation ( BMT ) , otherwise autologous BMT plan . PBSC may also harvest . Patients undergo harvest PBSC also receive G-CSF day 18-30 induction day 13-25 postinduction . - Second randomization : Patients randomize 1 4 consolidation treatment group . Good risk patient randomize arm II IV . Standard risk patient BMT consider inappropriate randomize arm II IV BMT consider appropriate randomized arm I III . Patients 4 total course therapy prefer randomized arm I II 5 total course therapy prefer randomized arm III IV . - Arm I : Six eight week follow completion induction , patient receive fourth course therapy comprise cyclophosphamide IV 1 hour 2 day , follow 24 hour later total body irradiation ( TBI ) 4 day , follow 24 hour later reinfusion bone marrow . Patients receive cranial irradiation daily 3-5 day prior TBI . - Arm II : Patients receive fourth course comprise mitoxantrone IV day 1-5 cytarabine IV 2 hour every 12 hour day 1-3 . - Arm III : Patients receive fourth course comprise idarubicin IV day 1 2 , cytarabine arm II , etoposide IV 1 hour day 1-3 fifth course comprise cranial irradiation , TBI , BMT arm I . - Arm IV : Patients receive 4th course comprise idarubicin , cytarabine , etoposide arm III 5th course comprise mitoxantrone cytarabine arm II . - PBSC support : Optional PBSC reinfused completion course 4 ( arm I II ) course 5 ( arm III IV ) begin sooner 24 hour completion BMT . - CNS therapy : Patients receive cytarabine intrathecally time diagnostic lumbar puncture , 3 day week cerebral spinal fluid clear , every 2 week completion consolidation . PROJECTED ACCRUAL : A minimum 2,000 patient accrue study 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Amsacrine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : De novo secondary acute myeloid leukemia morphologic type Acute promyelocytic leukemia also enter MRC ATRA trial No blastic transformation chronic myeloid leukemia PATIENT CHARACTERISTICS : Age : 15 physiologic 59 Patients intensive therapy consider inappropriate may enter protocol MRCLEUKAML11 successor Performance status : Any status Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No concurrent active malignancy Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior cytotoxic chemotherapy leukemia Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2002</verification_date>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>neutropenia</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
</DOC>